PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com
Clinical Trials
Related News

Treatment Of Children With Short Stature At An Age Of 3-7 Years Who Were Born Small For Gestational Age

Phase 3
Completed
Conditions
Growth Disorders
First Posted Date
2005-09-15
Last Posted Date
2007-05-03
Lead Sponsor
Pfizer
Target Recruit Count
110
Registration Number
NCT00174408

Celecoxib Versus Diclofenac In The Treatment Of Osteoarthritis Of The Hip

Phase 4
Completed
Conditions
Osteoarthritis, Hip
First Posted Date
2005-09-15
Last Posted Date
2006-12-05
Lead Sponsor
Pfizer
Target Recruit Count
250
Registration Number
NCT00174317
Locations
🇬🇧

Pfizer Investigational Site, Wigan, United Kingdom

PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients

Phase 1
Completed
Conditions
Carcinoma, Non-Small Cell Lung
First Posted Date
2005-09-15
Last Posted Date
2006-11-08
Lead Sponsor
Pfizer
Target Recruit Count
39
Registration Number
NCT00174356
Locations
🇨🇦

Pfizer Investigational Site, Hamilton, Ontario, Canada

Assessment Of Duration Of Action, Safety & Toleration Of UK369,003 and Cialis In Patients With Erectile Dysfunction

Phase 2
Completed
Conditions
Impotence
First Posted Date
2005-09-15
Last Posted Date
2006-07-25
Lead Sponsor
Pfizer
Target Recruit Count
300
Registration Number
NCT00174486

Prevention of Growth Retardation by Early Treatment With Growth Hormone (GH) in Children With CJA Treated by Corticosteroid Therapy

Phase 3
Terminated
Conditions
Endocrine System Diseases
Interventions
Drug: Somatropin
First Posted Date
2005-09-15
Last Posted Date
2012-12-04
Lead Sponsor
Pfizer
Target Recruit Count
21
Registration Number
NCT00174291
Locations
🇫🇷

Pfizer Investigational Site, Paris, France

Treatment With Recombinant Human Growth Hormone (GH) in Children With Short Stature Secondary to a Long Term Corticoid Therapy

Phase 3
Terminated
Conditions
Endocrine System Diseases
Interventions
Drug: Somatropin
First Posted Date
2005-09-15
Last Posted Date
2012-12-04
Lead Sponsor
Pfizer
Target Recruit Count
30
Registration Number
NCT00174187
Locations
🇫🇷

Pfizer Investigational Site, Paris, France

A Study to Investigate the Pharmacokinetics, Safety and Tolerability of Voriconazole in Children

Phase 1
Completed
Conditions
Neutropenia
First Posted Date
2005-09-15
Last Posted Date
2011-05-10
Lead Sponsor
Pfizer
Target Recruit Count
49
Registration Number
NCT00174473

Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients

Phase 2
Completed
Conditions
Breast Neoplasms
First Posted Date
2005-09-15
Last Posted Date
2011-04-22
Lead Sponsor
Pfizer
Target Recruit Count
46
Registration Number
NCT00174343
Locations
🇫🇷

Pfizer Investigational Site, St. Cloud, France

A Methodological Open Label Cross-Over Controlled Study To Assess The Effect Of Drugs On Ventricular Repolarization and QT Interval At Fixed Heart Rate Under Autonomic Blockade

First Posted Date
2005-09-15
Last Posted Date
2006-11-08
Lead Sponsor
Pfizer
Target Recruit Count
36
Registration Number
NCT00174512
Locations
🇬🇧

Pfizer Investigational Site, Manchester, United Kingdom

Study Aimed At Improving Height With Genotonorm In Children Born Little And/Or Light With Growth Retardation At The Age

Phase 3
Completed
Conditions
Fetal Growth Retardation
Interventions
Drug: Genotonorm (Somatropin)
First Posted Date
2005-09-15
Last Posted Date
2010-06-15
Lead Sponsor
Pfizer
Target Recruit Count
57
Registration Number
NCT00174252
Locations
🇫🇷

Pfizer Investigational Site, Vandoeuvre Les Nancy, France

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy